FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Guide on MDR Reporting

[ Price : $8.95]

FDA releases a final guidance on Medical Device Reporting (MDR) for Manufacturers that is intended to assist manufacturers with me...

FDA Clears 2 Medicrea Pediatric Spinal Devices

[ Price : $8.95]

FDA clears two Medicrea Group 510(k)s for its PASSXS posterior fixation and LigaPASSXS band connector components designed to addre...

FDA Guide on Neurological Devices Targeting Disease Progression

[ Price : $8.95]

FDA posts a guidance on Clinical Considerations for Investigational Device Exemption (IDEs) for Neurological Devices Targeting Dis...

Documents Show How Contentious Woodcocks Exondys Decision Was

[ Price : $8.95]

New CDER review documents embedded in a just-released approval package for Sareptas controversial Duchenne drug Exondys 51 (etepli...

Lawmakers Call for Probe on Drug Pricing Collusion

[ Price : $8.95]

Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) ask the Justice Department and the Federal Trade Commission to investig...

New CDRH Program to Leverage Patient Perspectives

[ Price : $8.95]

CDRH introduces a new program on the Patient and Care-partner Connection to allow patients and their organizations to dialog with ...

Lupin Says it Corrected GMP Issues at Indian Drug Plant

[ Price : $8.95]

Lupin says it has resolved GMP deficiencies cited by FDA during an inspection in March at its Goa, India manufacturing plant.

FDA Orphan Status for AbbVie Lung Cancer Drug

[ Price : $8.95]

FDA grants AbbVie an Orphan Drug Designation for veliparib, an oral poly (adenosine diphosphate-ribose) polymerase (PARP) inhibito...

Comments Sought on Informed Consent Requirements Estension

[ Price : $8.95]

Federal Register Notice: FDA asks for comments on a request for OMB to extend an information collection on The Protection of Human...

Dont Cave on Off-label Speech: Professors to FDA

[ Price : $8.95]

Law school professor Christopher Robertson and medical school professor Aaron Kesselheim urge FDA to continue to stand on principl...